Ratings Dong-E-E-Jiao Co.,Ltd.

Equities

000423

CNE0000006Y9

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 28/04/2024 BST			5-day change	1st Jan Change
67.61 ^CNY	+1.52%		-1.76%	+37.08%

04-25	Dong-E-E-Jiao Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-12	Dong-E-E-Jiao Forecasts Up to 55% Jump in Q1 Profit	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

With an expected P/E ratio at 31.47 and 26.91 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
DONG-E-E-JIAO CO.,LTD.	+37.08%	6.01B		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-17.43%	4.4B		C+
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.46%	3.17B		B-
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+0.51%	3.07B		C
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-3.53%	2.51B	-	D+
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+41.15%	1.88B		-
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-5.15%	1.73B	-	-
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B	-	-
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-10.38%	1.58B		C-
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+36.02%	1.4B		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes